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DNA copy number changes define spatial patterns
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Genetic heterogeneity between and within tumours is a major factor determining cancer
progression and therapy response. Here we examined DNA sequence and DNA copy-number
heterogeneity in colorectal cancer (CRC) by targeted high-depth sequencing of 100 most
frequently altered genes. In 97 samples, with primary tumours and matched metastases from
27 patients, we observe inter-tumour concordance for coding mutations; in contrast, gene
copy numbers are highly discordant between primary tumours and metastases as validated
by fluorescent in situ hybridization. To further investigate intra-tumour heterogeneity,
we dissected a single tumour into 68 spatially defined samples and sequenced them
separately. We identify evenly distributed coding mutations in APC and TP53 in all tumour
areas, yet highly variable gene copy numbers in numerous genes. 3D morpho-molecular
reconstruction reveals two clusters with divergent copy number aberrations along the
proximal–distal axis indicating that DNA copy number variations are a major source of
tumour heterogeneity in CRC.
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C
ancer heterogeneity is a major driving force for tumour
progression, metastasis and therapy resistance, and
poses a major challenge in personalized cancer medicine1.
Individual patterns of single-nucleotide variations (SNV) and
DNA copy number variations (CNV) occur in tumours
both between patients (inter-patient) and within single patients
(inter-tumour). In addition, spatially separated, molecularly
diverse areas may exist within tumours, defined as intra-tumour
heterogeneity2. These levels of heterogeneity are the result of
intrinsic mechanistic processes, such as inherent genomic
instability, clonal selection and competition, and tissue specific
tumour-host interactions3–7.
Colorectal cancer (CRC) is one of the best understood solid
cancers8,9. The mutational status of CRC determines targeted
treatment options. RAS and BRAF wild type tumours frequently
respond to anti-EGFR therapy, whereas mutant tumours are
refractory due to primary resistance. Importantly, the emergence
of mutations within the KRAS, NRAS and BRAF oncogenes10–12
in tumours previously tested to be RAS and BRAF wild type often
results in secondary resistance. However, high-depth massive
parallel sequencing analyses revealed undetected low-frequency
KRAS mutant clones already present in primary cancers10,11.
This suggests the existence of intra-tumour heterogeneity and
subsequent clonal selection for these mutations as a major
determinant of therapy outcome in CRC. Importantly, spatially
different areas of a tumour may harbour individual mutational
patterns, enabling outgrowth of sub-clones, which slip through
mono-sampling diagnostics3,13.
Yet, the mutational status of KRAS, NRAS, BRAF and other
proto-oncogenes and tumour suppressor genes does not account
for all cases of resistance to targeted therapy. A particularly
important mechanism besides genomic variations within
coding regions are variations in gene copy numbers (CNVs).
These comprise focal amplifications, aneuploidy or loss of
heterozygosity, for instance in tumour suppressors like APC
and TP53. The impact of CNVs on therapy resistance has already
been proven; for instance, CRC patients with amplifications in
KRAS, ERBB2, MET and FGFR1 show poor prognosis and
resistance to anti-EGFR therapy14,15.
Thus, genetic heterogeneity at both the SNV and the CNV level
can be a major obstacle to successful therapy and is a challenge
for mono-sampling diagnostics. Although several studies have
looked at genetic heterogeneity in CRC16–18, open questions
remain concerning the number of genes involved, the distribution
and nature of genetic aberrations between primary and metastatic
lesions, and sampling effects. Furthermore, information on
molecular differences between primary, synchronous and
metachronous tumour samples following therapy is still limited.
To address the contributions of SNVs and CNVs to CRC
heterogeneity, we performed a detailed analysis of inter-patient,
inter-tumour and intra-tumour heterogeneity. Using a CRC-
specific DNA sequencing panel covering 100 genes, we assessed
mutational patterns and CNVs using ultra-deep sequencing and
validated CNVs by fluorescent in situ hybridization (FISH). We
examined 97 samples from 27 CRC patients to study inter-patient
and inter-tumour heterogeneity (Fig. 1a,b) where we found little
genetic heterogeneity at the mutation level but strong CNV
heterogeneity between and within each patient. Furthermore,
we performed an in-depth analysis of 68 samples from a single
primary tumour to assess intra-tumour heterogeneity. Serial
sections of the tumour, each divided into the luminal, deep
invasive and lateral fronts, were sequenced along the proximal–
distal axis of the colon (Fig. 1c–e) and genetic alterations,
validated by FISH and shallow whole-genome sequencing (WGS),
were mapped to a three-dimensional (3D)-model of the tumour.
We find a homogeneous distribution of genetic mutations, yet
strongly diverging numbers of DNA copy numbers in multiple
genes implicated in tumour progression and therapy response,
such as CDX2, CARD11, MMP9 and BRCA2. This work indicates
that regional differences in gene copy numbers are an important
aspect of tumour heterogeneity in CRC. Our results thus propose
implementation of broader clinical routines taking into account
both DNA mutations and copy number changes.
Results
SNVs are highly concordant between tumours of the same patient.
To evaluate inter-patient and inter-tumour heterogeneity, we
analysed 27 CRC patients (40% stage III; 60% stage IV), each with
a primary tumour and at least one metastasis to the lymph node,
liver, retro peritoneum, lung, skin, small bowel, soft tissue, ovary,
uterus, brain or rectum together with matched healthy tissue.
(Fig. 1a,b and Supplementary Fig. 1).
We performed targeted high-depth sequencing (mean depth
1,500 reads) for genomic areas comprising 100 genes using a
custom-designed CRC panel (Supplementary Fig. 2a and
Supplementary Data 1). We detected 88 distinct non-synonymous
mutations in 20 genes when compared with the respective normal
tissue samples (Fig. 2a). TP53 was the most commonly mutated
gene, aberrant in 21 patients (78% of cohort), followed by APC in
19 patients (70%). KRAS (12 patients, 44%) harboured the
commonly described variants G12D, G12C, G12V, G13D, Q61H,
K117N and A146V. FBXW7 was mutated in six patients (22%),
and four of these exhibited the known S582L variant. In addition
to these commonly detected CRC mutations17,19, we identified
further mutations, for instance in CDX2, WFDC2 and MMP17.
The CDX2 mutation results in an amino acid deletion (p.248delK)
located in the homeobox domain of the encoded protein. One
patient carries a WFDC2 (also known as HE4) mutation (c.C13A,
p.R5S). A similar mutation (R5H) was described previously in the
large intestinal cell line Gp5D (ref. 20).
Only four patients (15%) displayed inter-tumour heterogeneity
of SNVs, defined as discordant mutational patterns in the samples
originating from one patient (Fig. 2b). Patient D3 carries a private
mutation in MMP17 in the primary tumour (c.G371A, p.R124K),
which is absent from the synchronous metastasis. Three patients
carry mutations in metastatic samples not detected in the primary
tumour samples: TCF7L2 (c.T631G, p.F211V, liver metastasis of
patient D23), GNAS (c.G2531A, p.R844H in one of three lymph
node metastases of patient D26), CARD11 (c.C1267T, p.R423W)
and TP53 (c.A736G, p.M246V; Fig. 2b). The latter two mutations
were found in a post-chemotherapy lung metastasis of patient
D27, but were absent in the matched pre-chemotherapy primary,
lymph node and brain metastasis samples. All discordant
mutations were verified by either Sanger sequencing, primer
extension HPLC-based SNuPE (Supplementary Fig. 3) or by
re-sequencing on a MiSeq Illumina platform.
In summary, our deep sequencing results indicate mainly
concordant SNV patterns within each CRC patient, even in
metachronous metastases resected long after the primary tumour.
For example, patient D41 displayed concordant SNV patterns in a
small bowel metastasis removed 60.5 months after the primary
colon tumour and had received both targeted and chemotherapy
during that period. We also examined the cohort for silent
mutations as well as variants residing in intron regions covered by
the panel (Supplementary Fig. 4). While primary and metastatic
samples of each CRC patient were highly concordant with respect
to driver-gene alterations, they display clear differences in
intronic and synonymous mutations.
CNVs are highly discordant between tumours from the same
patients. Next we determined CNVs from our panel-sequencing
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data by employing CNVPanelizer21, an algorithm specifically
designed to estimate copy number frequencies using targeted
massive parallel sequencing data. We found CNVs deviating from
the diploid state of normal tissues in 74 of 100 genes represented
by the CRC panel. The most frequent gene copy gain was detected
for CDX2 (13q12.3; 82% of samples) and WFDC2 (20q13.12;
56%). The tumour suppressor SMAD4 located on chromosome
18q21.1 was frequently affected by gene copy loss (53%; Fig. 2c).
Furthermore, we found recurring amplifications of chromosomal
regions carrying AMER1, CARD11, PTK2, PREX2 and EGFR.
We found a high level of inter-patient CNV heterogeneity, but
in contrast to the SNV data presented above, we also detected a
high level of inter-tumour CNV discordance within individual
patients (Fig. 3, Supplementary Fig. 5). For instance, patient D4
displays multiple DNA copy number differences between the
primary tumour (D4P7) and the three metastases (D4M8, D4M9
and D4M10). CARD11 CNV was diploid in the primary tumour,
but increased in all three metastases. SMAD4 copy numbers
decreased specifically in the metastasis D4M10. MMP9 showed a
copy number increase in metastasis D4M9 and D4M10, but not
in the primary and D4M8. Note that D4M8 was resected 2
months before the primary carcinoma (D4P7), while D4M9 and
D4M10 were removed 5 months and 2 years, respectively, after
the primary carcinoma and intermittent FOLFOX therapy.
CARD11 showed a copy number gain in the retroperitoneal
metastasis of patient 34 (D34M107), but not in the primary
tumour (D34P105). Notably, we did not detect any specific CNV
pattern typical of either metastases or primary tumours (see
‘Methods’ section ‘study of genetic and patient characteristics’).
To validate our findings regarding CNVs identified by
CNVpanelizer, we investigated SOX11, CDX2, MMP9, CARD11
and EDEM2 copy numbers in 41 tumour sections by gene-specific
FISH. SOX11 exhibited two alleles both by CNVPanelizer and
FISH. In agreement with CNVPanelizer data, we observed
amplification in CDX2 and MMP9 in all samples from patients
D8 and D2, respectively. FISH analysis also confirmed the high
degree of inter-tumour CNV (Fig. 4a,b). For instance, we found
the metastasis-specific copy number gain for CARD11 in patient
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Figure 1 | Experimental set up for the detection of tumour heterogeneity in CRC. (a) Inter-patient and inter-tumour heterogeneity was investigated in 27
patients with 31 primary tumours and 66 metastases from different organs. Five patients are shown in detail (D4, D8, D27, D41 and D50). (b) Detailed
information on the cohort studied. (c) Intra-tumour heterogeneity was investigated in a single stage II CRC tumour (tumour depicted in pink, colon in
orange) which was isolated entirely and separated into 5 individual blocks. Each block was sectioned completely and each set of 15 sections was grouped
together. Each section was divided into four compartments (A, B, C and D), resulting in a total of 68 samples used for massive parallel sequencing analysis.
(d) Detailed information on the stage II CRC tumour studied. (e) H&E staining of one representative section depicting compartments A, B, C and
D corresponding to the left and right lateral tumour regions, and the luminal and deep invasive front, respectively.
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D4 for both liver metastases (average copy number 3.26, 3.78 and
4.54, respectively). Furthermore, we detected CNV gains and
inter-tumour CNV heterogeneity in multiple patients by FISH,
which did not reach significance in the CNVPanelizer analysis,
such as different levels of amplification of CDX2 (patient D8,
see above) and EDEM2 in patient D10. Overall, FISH and
CNVPanelizer data exhibited good correlation (r¼ 0.655, see
Supplementary Fig. 6a).
We used centromeric FISH probes to distinguish local gene
copy gains from aneuploidy. Comparing gene counts to
centromere counts, we found that CARD11, CDX2, EDEM2,
and to a minor extent, EGFR displayed aneuploidy (parallel gains
in centromere and gene signal counts), whereas MMP9 showed
only local gene amplification in multiple independent samples
(Supplementary Fig. 6b). Interestingly, FISH analysis revealed not
only significant differences between the specimens, but also
showed CNV variability between adjacent cells (usually 50 cells
counted per sample) within the same sample (note the large
variation in bar graphs Fig. 4b). Taken together our analysis
detected different patterns of CNV in CRC, that is, between
primary tumours and metastases from the same patient and
between neighbouring cells within one tumour (Supplementary
Fig. 6b).
CNVs differ between distinct compartments within a tumour.
We asked whether genomic heterogeneity also exists between
different areas of the same tumour. To analyse intra-tumour
heterogeneity, we methodically disassembled an individual stage
IIA tumour (Fig. 1c–e). The tumour was divided into 5 blocks,
each sectioned and divided into 4 distinct compartments; left and
right lateral, and luminal and deep invasive front, yielding 68
independent DNA samples. Each sample thus originates from a
spatially distinct, well-defined compartment within the tumour.
A separate block containing healthy colon tissue was used as
control. We sequenced all DNA samples at a mean coverage of
1,800 reads, using the CRC panel (Fig. 5a, Supplementary Fig. 7
and Supplementary Data 2). We found that all parts of the
tumour carried the same APC (c.C4099T, p.Q1367*) and TP53
(c.G524A, p.R175H) variants, and no further SNVs in any
individual sample in coding regions covered by our panel (con-
firmed by Sanger and SNuPE validation; see ‘Methods’ section).
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Figure 2 | Overview of single nucleotide (SNV) and gene copy number variant (CNV) distributions in the inter-tumour heterogeneity study.
(a) Frequencies and distribution of genomic variants across all patients: frame-shift (purple), stop-gain (orange), deletion (pink) and missense mutation
(green). (b) Patterns of concordance and discordance within each individual patient. Colour code: shared mutations, that is, found in all samples from one
patient (dark blue); private mutation, that is, restricted to the primary tumour (pink); private mutation to metastasis (light blue). (c) Distribution of CNV,
called by CNVPanelizer, across all genes within the patient cohort. Colour code: gain of gene copy number (red); loss of gene copy number (blue).
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Our results show that the strong concordance of driver mutations
previously detected between primary and metastatic lesions
(see above) is also present in different areas of this single tumour.
We picked up a few non-coding or synonymous mutations in
several regions (Supplementary Fig. 8).
We next investigated CNVs in all 68 samples by CNVPanelizer.
We detected typical alterations previously described in CRC, for
example, loss of the short arm of chromosome 17 harbouring
TP53 and gain of the long arm of chromosome 20 with GNAS,
EDEM2 and MMP9 genes22 (Fig. 5a). Importantly, patterns of
CNV differed between the individual samples sourced from
different regions of the same tumour.
We independently analysed intra-tumour copy number
heterogeneity using FISH analysis on CARD11, MMP9, BRCA2,
EGFR and TP53 (12–18 samples per gene; Fig. 5b). Data from
FISH confirmed the existence of different levels of CNV within
the tumour analysed, and furthermore indicated widespread
aneuploidy (Supplementary Fig. 9c). Analysis of CNV by FISH
and CNVPanelizer were in good agreement with a correlation
coefficient of r¼ 0.621 (Supplementary Fig. 9a). We also used
quantitative reverse transcription PCR to validate CNVs affecting
TP53, MMP9, GNAS, EDEM2, SOX9, APC, SMAD4, MAP2K4
and HDAC3 genes in 43 samples, and once again could confirm
the CNVpanelizer results (correlation coefficient r¼ 0.7936,
Supplementary Fig. 9b). In addition to FISH and qPCR validation
of CNV aberrations, we performed shallow WGS on 10 distinct
areas of this tumour and a matched normal tissue. CNV values as
obtained from WGS displayed a strong correlation to those
derived from panel sequencing (r¼ 0.821; Fig. 6a). These data
corroborate the existence of intra-tumour CNV discordance
in CRC.
3D tumour reconstruction reveals spatial patterns of CNV.
To visualize the spatial distribution of intra-tumour CNV
heterogeneity, we assembled a morphological model of this
tumour in 3D and superimposed the CNV data onto the
reconstructed tumour’s architecture, encompassing the different
compartments (left and right lateral, luminal and deep invasive
front). Mapping of individual CNVs (specifically MMP9,
CARD11 and BRCA2, all validated by FISH), onto the 3D model
showed regional, but distinct spatial patterns (Fig. 6b–d; see
Supplementary Fig. 12 for additional gene patterns and
Supplementary Software 1 for an interactive 3D experience). For
instance, BRCA2 and ATM were assigned the highest DNA
copy number gains in the luminal region, EDNRB in the lateral
compartments, and HDAC2 in a subregion of the invasive front.
We performed agglomerative hierarchical clustering of the
CNVs recovered in all 68 tumour samples. Two highly divergent
clusters were found (Fig. 7a; Supplementary Table 1; and
Supplementary Fig. 10). Each cluster was characterized by CNVs
in distinct genes: in cluster 1 CSMD3, PTK2, BRCA2, PREX2 and
BRAF displayed copy number gains, while NOTCH3 showed copy
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number loss. In cluster 2, CARD11, MMP9 and HDAC1 were
amplified (P values in Supplementary Table 2). Strikingly, when
the clusters were mapped onto the 3D model, we found that the
two clusters were distributed between the proximal and distal axis
of the tumour (Fig. 7b, Supplementary Movie 1). Thus, our
comprehensive spatial reconstruction revealed CNV differences
between and across distinct compartments of a primary CRC,
despite stable and uniform patterns of driver mutations.
Discussion
Our study investigated inter-tumour and intra-tumour hetero-
geneity in CRC. We found a striking discordance between
primary tumours and metastases, as well as within a single
tumour at the level of gene copy numbers. Three-dimensional
reconstruction of a primary tumour revealed a spatial distribution
of chromosomal alterations clustered along the proximal–distal
axis of the tumour. In contrast, we found a high concordance in
known driver mutations within both the reconstructed tumour
and the primary/metastases pairs taken from the same patient.
High concordance was present in driver mutations such as APC,
KRAS, NRAS, PIK3CA and SMAD4, in addition to AMER1,
TCF7L2, CARD11 and the EGFR family members EGFR and
ERBB3. Our analysis indicates that gene CNVs are the major
source of tumour heterogeneity in CRC development.
We found chromosomal aneuploidy and heterogeneity far
more prevalent than hot-spot SNVs within driver oncogenes
among multiple tumours between patients and within an
individual patient. Importantly, within the limited genomic area
the panel covers, some intronic and synonymous mutations show
a heterogeneous pattern (Supplementary Figs 4 and 8). This could
indicate that genome wide sequencing may additionally reveal
clonal SNVs, which our analysis does not cover. CNV hetero-
geneity was inferred using CNVPanelizer and validated by FISH
analyses, ruling out false detection of PCR amplification and
FFPE artifacts; the robustness of the CNV results was additionally
confirmed by WGS analysis of selected samples. Among the genes
amplified was MMP9, encoding a matrix metalloprotease, whose
overexpression is associated with tumour progression and
invasion23. Furthermore, MMP9 copy number gain has been
associated with gene overexpression in gastric cancers24.
Interestingly, we found increased MMP9 gene copy number in
the two metastases of patient D2 when compared with the
matched primary sample, as well as intra-tumour heterogeneity of
MMP9 along the proximal–distal axis (Fig. 4b and Supplementary
Figs 6b and 9c). Similarly, CDX2 exhibited copy number gains
ranging from duplication to more than 20-fold amplification.
CDX2 was identified as a lineage-specific homeobox transcription
factor involved in intestinal epithelial cell proliferation and
differentiation25 and has recently been proposed as a prognostic
and predictive marker for stage II and III CRC (ref. 26). Our
analysis therefore suggests that CNV heterogeneity could endow
cells with functional traits important for tumour progression,
invasion or metastasis.
The data we presented does not itself lead to functional
conclusions on tumour heterogeneity, as would be possible
from a joint analysis of CNV and transcriptome data. While
other studies have shown clear correlation between CNV and
gene expression in gastric cancers24,27, this need not be the case
for all CNV studies. However, due to limited material we were not
able to conduct expression studies on our cohort.
Sequencing of multiple neighbouring serial sections from a
non-metastasized colon tumour detected ubiquitous mutations in
APC and TP53 as well as copy number gains in the GNAS and
EDEM2 genes on the long arm of chromosome 20 and consistent
loss of heterozygosity of TP53. This analysis provides evidence for
the existence of a common dominant ancestor clone proposed
earlier28. However, the analysis also discerned two separate cell
populations by CNV analysis and hierarchical clustering. After
superimposing the two clusters onto the 3D reconstruction of the
tumour, two sub-populations at the proximal and distal ends
manifested. This finding supports the so-called ‘Big-Bang model’
of CRC described recently4. The model suggested that a small
number of genetic alterations are either public to the entire
tumour, or exhibit enrichment at specific sides of the tumour.
Our analysis indeed found a high level of DNA copy number
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Figure 4 | FISH analysis of inter-tumour heterogeneity.
(a) Representative FISH for CDX2, MMP9, EDEM2 and CARD11 in orange and
centromeres of individual chromosomes in green. Scale bar depicts 10 mm.
(b) Quantification of FISH using probes for CDX2, MMP9, CARD11 and
EDEM2 reveals differential gene copy numbers between matched primary
and metastatic samples. A SOX11 probe was used as a control. 50 cells
randomly selected were counted in each sample. The distribution of signals
per sample is depicted. Checkered boxes indicate samples from tumour
exposed to chemotherapy. Wilcoxon signed rank test, *Po0.05, **Po0.01
and ***Po0.001. Box shows 25th and 75th percentiles and sample median
as horizontal line, whiskers show maximum and minimum points.
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heterogeneity between proximal and distal compartments of the
tumour. Using FISH, we also discovered DNA copy number
heterogeneity at the level of individual cells. However, we cannot
distinguish from our data whether this results from a dynamic
progressive process or if it is the result of intermingling of
different sub-clones during an early ‘Big-Bang’ scenario. Clearly,
our investigation does not reach the sensitivity of single intestinal
gland analysis of previous studies4,29. However, we distinguish
compartments of the tumour–the invasive front, luminal and
lateral areas as well as proximal and distal sides–where we find
distinct CNV patterns for multiple genes implicated in tumour
development.
Many of the CNVs detected are likely to reflect aneuploidy
rather than local gene amplification (Supplementary Figs 6b
and 9c). Cancer aneuploidy has been associated with adverse
prognosis in several types of cancers30–32. It is the most common
genomic alteration encompassing 480% of CRCs and has been
implicated in drug-resistance30. Chromosomal instability is
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hypothesized to adopt the role of a ‘genomic modifier’ once
induced via, for example, mitotic stress33. This is reflected by
our discovery that each tumour sample analysed exhibits an
individual CNV pattern, even within a single patient with
concordant hot spot SNVs (Fig. 3). Moreover, our 3D model
suggests that CNVs might exert this modification potential in
spatially different areas within a single tumour. Such a scenario
would imply a high potential for tumour adaptation towards
targeted and chemotherapy, and would also call for more
stringent cancer therapy specifically fatal for aneuploid cells34.
Previous studies analysing the genetic landscapes of patient-
individual primary and metastatic samples in CRC have revealed
shared hot-spot mutations6,16,18. While our study is in line with
these findings, we additionally validated cases of discordance in
MMP17, TCF7L2, GNAS, CARD11 and TP53. The GNASmutation
affects the G-protein alpha subunit and can potentially impinge on
Wnt and MAPK signalling35,36. The MMP17 mutation, localized
in close juxtaposition to the peptidase segment of the encoded
protein. MMP17 has been implicated in breast cancer as a positive
modifier of EGFR signalling37. The TCF7L2 mutation is located
within the beta-Catenin binding domain and potentially modulates
Wnt/beta-Catenin signals38–40. The CARD11 and TP53 mutations
detected only in a lung metastasis following chemotherapy could
contribute to the activation of the NF-kB pathway41 and to
abrogation of TP53 function42,43, respectively. Despite their low
prevalence, these discordant mutations can potentially act as
drivers of tumour progression or of therapy resistance in rare cases.
It is of note that CARD11 was also highly ranked among the
genes displaying intra-tumour CNV. Therefore, mutations and
CNV could complement each other in deregulating CARD11
function.
We propose that future diagnostic approaches should take
into account spatial heterogeneity and genomic aberrations on
multiple levels, particularly DNA copy number alterations.
Our work, encompassing 97 samples from 27 patients plus an
extended set of 68 samples from an in-depth analysis of a single
tumour has identified candidates for future comprehensive CNV
analysis to improve patient stratification.
Methods
Patient cohort and sample designation. Primary colorectal tumours with
matched multiple metastasis and normal colon tissue were collected from
27 patients for analysis of inter-patient and inter-tumour heterogeneity.
All patients had signed written consent as part of the clinical documentation
protocolled of the University Hospital Carl Gustav Carus at the Technical
University of Dresden. All tumour specimens were micro-satellite stable CRC.
The median age of patients in the cohort was 62 years (range 32–91). Detailed
clinical and histopathological data can be found in Fig. 1b and Supplementary
Fig. 1.
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For intra-tumour heterogeneity analysis, a single-stage IIA CRC tumour was
collected at the Charite´ Universita¨tsmedizin Berlin, Institute of Pathology, Berlin.
The patient was 77 years old at the time of tumour resection. The patient had no
lymph node or organ metastasis at time of surgery (TNM pT3pN0(0/17)G2R0L0V0).
No neoadjuvant therapy was administered to the patient before tumour isolation.
The complete tumour was divided into 5 FFPE blocks, which were subsequently
sectioned into 5–10 mm slices. Sections stained with haematoxylin and eosin (H&E)
were prepared out of every 15th consecutive section (one group), all other sections
were used for DNA isolation and FISH analysis. Before DNA isolation, each section
was divided into four parts designated by the letters A, B, C and D corresponding
to the left and right lateral tumour regions, and the luminal and deep invasive front
compartments, respectively (Fig. 1e), resulting in 68 samples. In addition, healthy
colon tissue was isolated and DNA prepared separately. Naming scheme for
samples is ‘patient’ ‘block’.‘group’ plus the letter A–D indicating compartment.
Healthy tissue sample has sample I.D.: 3.1-1 (patient 3. block 1.group 1) and
no compartment division.
This study has been approved by the ethics commissions at the University
Hospital Carl Gustav Carus/Technical University of Dresden (protocol
EK59032007) and the Charite´ Universita¨tsmedizin Berlin (protocol EA1/260/12).
Design of the colorectal cancer gene panel. To investigate the CRC-specific
genetic landscape, we designed a custom CRC panel. The panel is comprised of the
most commonly mutated or copy-number variant genes in micro-satellite stable
CRC (selected from the Cancer Genome Atlas (TCGA)39 and Genentech’s40
whole-genome sequence databases and the Catalogue of Somatic Mutations in
Cancer (COSMIC)44), as well as genes known to confer sensitivity or resistance to
drugs (as retrieved from the Comparative Toxicogenomics Database (CTD)45,
the Cancer Cell Line Encyclopaedia (CCLE)46 and the Genomics of Drug
Sensitivity in Cancer database (GDSC)47). The complete 100-gene panel
(Supplementary Fig. 2a,b) included primers for 793 amplicons, covering
125 bp-stretches of mainly exonic regions which were found to be mutated at least
in five different specimens present in the databases of TCGA and Genentech.
Targeted massive parallel sequencing. Targeted massive parallel sequencing
employed Ion Torrent PGM technology (Life Technologies) for primary data
generation and a MiSeq device (Illumina) as a second platform. All samples were
inspected by a pathologist and tumour tissue was determined by H&E staining.
Tumour tissue was macrodissected from slides and DNA was extracted using the
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GeneRead DNA FFPE kit (Qiagen). Quality and quantity of DNA was determined
by RNAse P quantification (Life Technologies).
Whenever possible, 10 ng of DNA were used for multiplexed PCR amplification
with the Ion Ampliseq Library kit (Life Technologies), using two amplicon pools
per DNA sample. Samples were ligated to Ion Xpress Barcode Adapters (Life
Technologies) and purified using Agencourt AMPure beads (Beckman Coulter).
Two sample were combined on a 316v2 chip and sequenced on an Ion Torrent
PGM device (Life Technologies) with an average read depth of 1,500 (range
666–3,532) for the inter-tumour heterogeneity cohort and 1,800 (range 920–2,739)
for the intra-tumour heterogeneity analysis. Filtered data are available in
Supplementary Data 1 and 2 for inter- and intra-tumour studies respectively.
Sequence reads were aligned to the GRCh37 sequence using the Torrent
Mapping and Alignment Program (TMAP; Life Technologies). Aligned reads450
nucleotides with a mapping quality 44 were kept and trimmed to amplicon
boundaries, using in-house Python scripts. Variants were called on the processed
reads using the Torrent Variant Caller (TVC; Life Technologies) under the ‘strict’
setting as specified by the IonTorrent Suite. A further filter was added to remove
variants within homopolymer regions 44 nucleotides in length and variants that
were also found in the normal tissue yielding reliable somatic variants. All variants
from samples belonging to the same patient were then merged. Reference and
alternate read counts were extracted directly from the original read alignments for
the samples in which the matching variants were not called using an in-house
Python script.
Each variant was annotated with several types of biological information using
an annotation framework called SoFIA48. A threshold of quality Q¼ 50 was
applied to reduce false positive results due to FFPE material (Supplementary
Fig. 2c).
MiSeq (Illumina) re-sequencing. We used a MiSeq device (Illumina) as a second
platform for validating sequencing results for patients D11 and D30 using the same
custom CRC panel. DNA (10 ng) from FFPE embedded tumour tissue was
prepared using the Ion AmpliSeq Library Kit 2.0 (Life technologies) for the CRC
panel, followed by library preparation using the NEB Next Ultra DNA Library Prep
kit (end repair, A-tailing, adaptor ligation and amplification; NEB, E7370S) and
NEB Next Multiplex Oligos provided for Illumina (NEB, E7335S). 100 pM of
resulting library DNA was pooled, all samples from one patient were pooled
together. The average read output was 4.6 106 reads.
Shallow whole-genome sequencing. DNA from samples 3-4D, 5-3D, 6-6B, 5-2D,
5-4B, 2-2B, 2-3B, 2-4A, 3-3A and 3-4A was prepared with TruSeq Nano DNA
Library Prep Kit (Illumina) according to the manufacturer’s protocol: 100 ng of
genomic DNA were fragmented to 350 bp using Covaris LE220 system (Covaris,
Inc.). Fragments were end-repaired, A-tailed, adaptor ligated and PCR amplified
(8 cycles). The final libraries were validated using Agilent Tapestation 2200
(Agilent Technologies) and Qubit flourometer (Invitrogen), normalized and pooled
in equimolar ratios. 101 bp paired-end sequencing was performed on the Illumina
HiSeq 4000 according to the manufacturer’s protocol. To match downstream
analysis requirements, only the first members of the read pairs were considered,
and were truncated to the first 50 bp. The resulting genome coverage was between
0.25 and 0.39 (0.64–0.79 for paired end reads). Data analysis were performed
following Scheinin et al.49
Validation of single-nucleotide variations. To validate NGS results we used the
Illumina platform, Sanger sequencing and Single Nucleotide Primer Extension/
HPLC method (SNuPE). MiSeq (Illumina) platform was used to re-sequence
several samples (described above). Sanger sequencing was used to validate SNVs
that occurred at an allele frequency higher than 10%, either using primers from our
CRC panel or newly designed primers. For mutations with allele frequencies below
10% we used SNuPE, as described in Hoogendoorn et al. and Tierling et al.50,51
This method allows validation of variants with allele frequencies down to 1%.
(see Supplementary Tables 3,4 and 6 for primer lists and Supplementary Fig. 3 for
validation examples).
Prediction of DNA copy number variations from NGS data. DNA CNV were
predicted by analysing the panel-sequencing data using CNVPanelizer21, which
compares tumour samples with a pool of non-matched normal tissue samples.
The algorithm combines bootstrapping the reference set with the subsampling of
amplicons associated with each of the target genes. This serves as a non-parametric
distribution estimation of the gene-wise mean ratio between healthy reference
samples and each tumour sample. To correct for different numbers of amplicons
per gene, a second subsampling step was applied. For the inter-patient and tumour
heterogeneity study we used the matched normal tissue as a reference. For the
intra-tumour heterogeneity study, blood samples from healthy individuals and
matched normal tissue were used as the reference. PCR duplicates were removed
and only CNVs with a P value o0.001 in both the bootstrapping and background
methods were called.
Fluorescence in situ hybridization. FISH was performed on 5 mm tumour
sections. We used commercially available and standardized probes for detection of
EGFR (Vysis LSI EGFR SO/CEP7 SG), TP53 (Vysis LSI TP53; Abott Molecular),
SOX11, CDX2, CARD11, BRCA2, EDEM2 and MMP9 (Empire Genomics).
Hybridization was performed according to manufacturer’s instructions.
Where possible we scored 50 cells per sample (inter-patient and inter-tumour
heterogeneity study) and 30 cells per sample (intra-tumour heterogeneity study) for
hybridization patterns using an Olympus microscope. Analysis was conducted
using ‘BioView solo’ (Abbott Molecular).
Quantitative polymerase chain reaction analysis. Four tumour samples and
matched normal tissue were analysed using 0.5 ng of FFPE DNA. An internal
control was integrated using normal colon tissue DNA from two patients without a
history of cancer. Analysis was performed using the 2(DDCt) approach. qPCR was
performed for APC, EDEM2, GNAS, HDAC3,MAP2K4,MMP9, TP53, SMAD4 and
SOX9 genes, the TERT gene served as a reference (Supplementary Table 5 for a list
of primers).
Study of genetic and patient characteristics. The relationships between the
genetic attributes of the tumours in the cohort and several patient characteristics
were investigated through the application of a series of tests to reveal potential
targets and biomarkers, and to find mechanistic explanations for observed genetic
variations. Two genetic attributes (mutation status and gene copy number) were
tested against (1) whether the tumour was a primary neoplasm or metastatic,
(2) whether the patient had received treatment or not, (3) disease stage, (4) whether
the primary tumour was in the right or left colon, (5) gender of the patient,
(6) whether the samples was derived from a lymph-node metastasis, (7) whether
the sample was derived from a liver metastasis. Primary tumours (P) and
metastases (M) were analysed together for characteristics 1 and 2. Primary tumours
and metastases were analysed separately for characteristics 3–5. Only metastases
were analysed for characteristics 6 and 7.
We corrected for inter-patient genetic similarity (the patient effect) using a
generalized linear mixed model with the ‘logit’ link function to model the binomial
nature of the phenotype values. In cases where there was only one sample from
each patient, a generalized linear model with a ‘logit’ link function was fit. In all
other cases, both the independent variable and the response variable were binomial
in nature and a Fisher Exact test was used.
The P values for the generalized linear models and generalized linear mixed
models were calculated using a chi-square test comparing the fitted model with the
null model in which only the patient effect was modelled. For each independent/
response variable combination the P values were corrected for multiple testing
using the Benjamini–Hochberg method. All analyses were implemented using
R and the libraries nlme (ref. 52) and ggplot2 (ref. 53).
Hierarchical clustering of genes. CNVs belonging to the 68 samples from the
intra-tumour heterogeneity study were clustered using pvclust (ref. 54), an
agglomerative hierarchical clustering algorithm that performs multiscale bootstrap
resampling to calculate an approximate unbiased P value for each identified cluster.
Bootstrapping was performed with 10,000 repetitions. The genes that best
distinguish between the clusters were determined by applying the non-parametric
Wilcoxon rank-sum test to the difference in gene copy number aberrations
between the clusters for each gene individually. The resulting P values were
corrected for multiple testing using the Benjamini–Hochberg method. The genes
with the most significant P values were chosen for validation according to the
methods described above.
Reconstruction of tissue architecture and 3D visualization. To obtain a
full spatial representation of the tumour and visualize intra-tumour genetic
heterogeneity, we generated a 3D micro-anatomic tumour model from consecutive
sections taken from all 68 tumour samples from one stage II CRC patient. H&E
stained slides were digitized with a 3D Panoramic 250 scanner (3D HISTECH).
Four different compartments (designated A, B, C and D, see Fig. 1e) were
annotated manually for each digital slide corresponding to the region used for
separate molecular analyses55. The shapes of these annotations were exported and
scaled into images of 1,776 562 pixels. As slides from five different blocks were
used to create the 3D model, a manual registration of those images was necessary.
Slices in the x-y-plane were stretched along the z-axis to preserve uniform
aspect ratio. As a consequence of the tumour’s overall macroscopic architecture,
the number of sections differs among tissue blocks. For this patient, block #1
represents normal tissue and was not used for reconstruction, block #2 is
represented by 20 samples, block #3 by 16, block #4 by 8, block #5 by 16 and block
#6 by 8 samples. Slight deformations of the sections are unavoidable due to the
softness of the tube-like colonic tissue. When serial tissue sections were placed into
embedding cassettes, discontinuities between them were minimized by careful
processing, however not eliminated completely. The position and rotation
of regions was adjusted manually, while the shapes were not changed
(rigid registration). In a fine adjustment step each region under-went further
minimal non-rigid transformation to improve reconstruction. Next, the MoMo
(morphology modeller) algorithm described in Klauschen et al.56 was used to
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create a 3D model for each region of the planar mask images containing the
shape information. Models were stored in.obj files and imported into Blender
(https://www.blender.org/), a 3D modelling tool, which was used for additional
smoothing of the model and exporting it into one.fbx file. Colouring information
was loaded from.csv files and passed to a shader that interpolates a value for each
vertex from all measured values depending on the squared distance between the
center of the measured region and the vertex. The data from the shader is mapped
back to the tissue sections by assigning the respective molecular feature value of a
subregion to the center voxel of the subregion in each histological plane for which
the molecular analysis was performed. Then the surface mesh colours are
interpolated between neighbouring centres. We used the 3D reconstruction and
colouring process to model the spatial distribution of the clusters found through
hierarchical clustering and the copy number for the genes MMP9, CARD11 and
BRCA2 in addition to CNV cluster information obtained by the method described
above. An interactive 3D visualization of the measured data (per gene and clusters)
can be downloaded by the reader using Supplementary Software 1. Supplementary
Table 7 lists the measured CNV data used for the 3D visualization shown in the
screenshot Fig. 6b–d. Representative macro images of tissue H&E sections used for
3D reconstruction can be found in Supplementary Fig. 11.
Data availability. Sequence data has been deposited at the European
Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under
accession number EGAS00001002150. The remaining data are available in the
article or the Supplementary Files or from the authors on request.
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